Research topics
Microbiome articles covering gut bacteria, microbial changes, microbiota research, and IBD disease mechanisms.
Page 5 of 12 · 570 articles
This study identifies a specific gut microbe (Turicimonas muris) and an immune pathway link by which a high-fat diet reduced experimental colitis severity in mice, suggesting diet–microbiome interactions can strongly...
This study describes a programmable, inflammation-responsive engineered probiotic aimed at targeting IBD flares by sensing calprotectin and delivering antioxidant and epithelial-protective factors — a concept that could...
This study suggests airborne, soil-associated microbes can change the gut microbiome and reduce colitis severity in mice — a possible explanation for lower ulcerative colitis rates in rural areas. If similar effects...
If donor ethnicity or specific microbial/metabolite signatures influence FMT success, results could help identify optimal donors or develop targeted microbiota-based treatments for ulcerative colitis.
This trial tests a safe, non-drug supplement (GlcNAc) as a precision-medicine approach for Crohn's disease based on a genetic variant that affects glycosylation. If successful, it could offer a new, well-tolerated...
This preclinical study suggests probiotic-derived extracellular vesicles may reduce intestinal inflammation and restore barrier function via PPARγ signaling and changes to the gut microbiome—an early step toward...
The ENS–gut microbiota field intersects with IBD research through shared mechanisms (neuroinflammation, neuro‑immune interactions) and potential microbiota‑based therapies, so mapping trends helps patients and clinicians...
The study describes a new berberine-containing nanocomplex that reduced inflammation and improved gut barrier function in cell, mouse, and organoid models of ulcerative colitis, suggesting a potential new direction for...
Microplastics are a widespread environmental exposure that this review links to biological changes relevant to IBD — intestinal barrier damage, microbiome shifts, and immune activation — so patients and clinicians may...
The study suggests FMT can clear mucosal adherent‑invasive E. coli (AIEC) in some people with Crohn’s disease and alters mucosal microbiome features linked to inflammation, which could be relevant to microbiome‑targeted...
This trial tests whether oral vancomycin can help children with atypical ulcerative colitis or PSC-associated colitis and whether changes in gut bacteria or metabolites explain response. If effective and safe, it could...
People with IBD who are treated with anti‑TNFα drugs commonly develop inflammatory or infectious skin problems. This study aims to clarify whether Staphylococcus aureus is more abundant in those lesions and whether its...
The study raises the possibility that perinatal exposure to nanoplastics could have lasting, sex-specific effects on gut health and make adult offspring more susceptible to intestinal inflammation. This may be relevant...
IL-22 links microbial metabolites to epithelial repair and inflammation; clarifying these pathways could inform future therapies or dietary/microbiome approaches to promote mucosal healing without worsening inflammation.
This review highlights a new, non-live microbiome-based therapy approach (probiotic-derived EVs) that could in future modulate gut immunity and barrier function without using live microbes. For people with IBD, such...
The study links a specific gut microbe and its metabolite to reduced inflammation and improved barrier function in ulcerative colitis models and cohort comparisons, suggesting a potential new microbiome-targeted therapy...
This trial tests an oral live biotherapeutic (MH002) aimed at restoring a healthier gut microbiome in people with mild-to-moderate ulcerative colitis. If effective and safe, it would offer a non-immunosuppressive,...
The study describes a targeted oral delivery system for 5-ASA that aims to concentrate drug release in the colon and also leverage inulin’s prebiotic/immunomodulatory properties—potentially improving effectiveness and...
Depression is common in Crohn’s disease and appears linked to immune and microbial signals from the gut. Understanding gut–brain mechanisms could improve how mood symptoms are detected and treated in people with IBD.
AMPs are central to gut immune balance and are being explored as new therapies for IBD and related gut diseases. For people with Crohn’s or IBD, understanding AMPs helps explain research directions aimed at restoring...
This trial tests standardized encapsulated fecal microbiota products as a microbiome-directed therapy for active Crohn’s disease, focusing on whether donor microbes engraft in the ileum and colon and whether that relates...
The paper presents a proof-of-concept immune-based assay to match donors and recipients for FMT in IBD, which could help explain variable FMT outcomes and improve donor selection if validated.
Intestinal barrier dysfunction is a likely driver of inflammation and flares in ulcerative colitis, so therapies that restore barrier integrity could help reduce disease activity and recurrence. This review highlights...
This mouse study connects fat malabsorption, increased gut permeability, microbiome shifts, and reduced oxalate transport to higher oxalate absorption and kidney injury—mechanisms relevant to enteric hyperoxaluria seen...
New colon-targeted formulations aim to concentrate treatment where inflammation is in ulcerative colitis, which could increase benefit and reduce systemic side effects. Formulation research like this is an early step...
The work links climate and sociodemographic context to IBD burden in tropical regions, which can influence diagnostic recognition, resource needs, and research priorities for communities where IBD is rising.
People with IBD commonly experience anxiety, depression, and other neurological symptoms. Understanding gut–brain axis mechanisms may help explain these comorbidities and point to future treatments.
This project tests whether common nanoplastics that people ingest could damage the gut barrier, alter gut microbes’ estrogen metabolism, and injure enteric nerves — processes that might increase risk or severity of IBD.
Researchers aim to build and study tiny gut phages (Microviridae) that are largely known only from DNA sequences. Learning how these phages shape microbial communities could help explain virome-linked changes seen in...
This project aims to map microbe-specific T cells in Crohn's disease using single-cell RNA and TCR sequencing. Findings could reveal antigen-specific mechanisms driving IBD and help lay groundwork for targeted...
This project could introduce a novel, microbiome-targeted oral therapy for Crohn’s disease if the Phase II trial confirms safety and clinical benefit; that matters because many patients need new options when current...
The microbiome is connected to IBD through effects on immune regulation and barrier function; advances in understanding could inform future microbiome-directed therapies that matter to people with IBD.
A potential link between ultra-processed food intake and Crohn’s relapse could influence dietary conversations for people in remission, but the current evidence is weak and not definitive.
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic...
This study describes a new microbiome-engineering approach that reduced inflammation in mouse colitis models by sequestering cysteine and altering T cell behavior. If followed up, it could point to novel future therapies...
FUT2-dependent intestinal fucosylation helps shape which gut microbes thrive and how the mucosa resists pathogens. For people with IBD, differences in FUT2 function and altered fucosylation may contribute to microbiome...
This study describes a novel colon-targeted microgel delivery system carrying an anti-inflammatory natural compound that, in a mouse model, reduced colitis signs and altered gut bacteria — a potential new strategy for...
Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.
People with stricturing Crohn’s disease currently lack effective medical treatments to prevent or reverse intestinal fibrosis; this trial explores a probiotic approach (and trehalose) aimed at stimulating autophagy, a...
The study links a common dietary fiber (green banana resistant starch) to microbiota changes and production of propionate that protect the colonic barrier and reduce inflammation in a mouse model of ulcerative colitis.
People with IBD may experience cognitive symptoms; this preclinical study identifies specific quercetin glycosides that protected mice from colitis-related cognitive decline via gut microbiota and tryptophan metabolism...
The study suggests that timing of eating (time-restricted feeding) may influence intestinal inflammation and gut microbiota in ways that could be relevant to IBD. If confirmed in humans, meal timing could be a low-cost...
A plant polysaccharide (PVP) reduced inflammation and preserved intestinal barrier proteins in a mouse model of ulcerative colitis, apparently by increasing a specific gut bacterium. This points to a microbiome-related...
Researchers are working to link specific gut microbes and their metabolites to host molecular changes in ulcerative colitis. This study maps candidate microbe–metabolite–host gene connections that could point to new...
If confirmed, molecular or microbial markers found at surgery could help identify Crohn’s patients at higher risk of postoperative endoscopic recurrence and inform closer monitoring or preventative strategies after...
Sarcopenia (loss of muscle mass/strength) was common among hospitalized adults with active UC and linked to inflammation, changes in blood metabolites (bile acids, acylcarnitines), and shifts in the gut microbiome.
The work links a PD risk gene (LRRK2 G2019S) to increased intestinal NET formation and enteric α-synuclein in mouse colitis, suggesting a neutrophil-mediated inflammatory route by which gut inflammation and microbiota...
Vitamin D deficiency is common in people with IBD and this study suggests correcting deficiency may help rebalance immune cells and the microbiome—potentially supporting inflammation control alongside standard...
